Transformational year for Oncimmune plc says Geoffrey Hamilton-Fairley, CEO

Geoffrey Hamilton-Fairley, CEO of Oncimmune LON:ONC, commented: “The last year has been transformational for Oncimmune with the period culminating in our listing on AIM and fundraising £11.0 million. With this funding in place we are continuing to deliver on the strategy set out at the time of our IPO.  “We have a Board with broad expertise in medical devices and public markets, distributor agreements signed giving us full coverage of the US for our EarlyCDT®-Lung test. In addition, the foundations have been laid for the commercial panel for the EarlyCDT®-Liver test, which is targeted to be complete in the second half of 2017, with EarlyCDT®-Ovarian thereafter. We are confident that we are well placed to deliver value from the strength our platform in early cancer diagnosis.  We look forward to updating the market on the NHS Lung Cancer Screening Trial in December, the transformation of our test from a central lab test to a “kit” and further product and commercial advances.”

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today gave DirectorsTalk full year results for the year ended 31 May 2016.

 

Financial highlights

 

·    £12.2m raised by the issue of equity in the year.

·    £4.2m of convertible loan notes were converted.

·    Revenues for the year were £0.43m (2015: £1.36m)

·    Operating costs before share based charges and exceptional items were £3.83 million (2015: £2.7m)

·    Cash balance at the year-end was £10.2m (2015: £1.3m)

 

Corporate and operational highlights

 

·    Corporate progress

o In May 2016, AIM IPO raising gross proceeds of £11.0 million

o In September 2015, acquisition of dedicated commercial testing facility for EarlyCDT®-Lung from Health Diagnostic Laboratory, Inc, with a net cash benefit of £1.56m

·    Developing the Board and Senior Management

o In November 2015, appointment of Dr Jim Jett as Chief Medical Officer

o In September 2015, appointment of Meinhard Schmidt as Non-Executive Chairman

·    EarlyCDT® platform progress

o In September 2015, encouraging early results based on 9,654 patients out of the 12,000 patient NHS Lung Cancer Screening Trial using EarlyCDT®-Lung test

o In May 2016, successful patent claim covering Oncimmune’s “panel assay” method for detection of cancer-related autoantibodies; portfolio consists of 275 patents in eight patent families

·    EarlyCDT®-Lung distributor agreements covering majority of US market

o Distributors increased from three to eight in the period and subsequently this has increased to 14

 

Post-period highlights

 

·    In July 2016, research agreements were signed with Egybiotech and Aarhus University Hospital in ovarian and liver cancer to validate panels of autoantibodies as diagnostic tests

·    In July 2016, CE mark for the reagents used in EarlyCDT®-Lung was obtained

·    In August 2016, following the death of Robert Page, Andrew Millet was appointed as an Executive Director and Chief Financial Officer

·    In September 2016, new data was published in the Journal of Thoracic Oncology on the effectiveness of the EarlyCDT®-Lung distinguishing between malignant and benign lung nodules

·    In June 2016, appointment of Julian Hirst as Non-Executive Director

·    In September 2016, appointment of Maarten Brusse as Chief Commercial Officer Asia Pacific

·    In October 2016, appointment of Carsten Schroeder as Non-Executive Director

 

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oncimmune Holdings PLC

    More articles like this

    Oncimmune Holdings report two further ImmunoINSIGHTS contracts signed

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

    Oncimmune signs go-to-market partnership with Synexa Life Sciences

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

    Oncimmune signs new commercial contract with Verily Life Sciences 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

    Oncimmune Holdings Notice of half year results

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

    Oncimmune achieves FY2021 revenue of £3.7 million

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its audited results for the year ended 31 May 2021 and provides an update on recent progress and the outlook for the current financial year.

    Oncimmune to evaluate the profile of patients using ImmunoINSIGHTS

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The